Wilcoxon-Mann-Whitney! [Nonparametrics]

posted by d_labes  – Berlin, Germany, 2018-06-19 15:25 (2001 d 02:04 ago) – Posting: # 18921
Views: 7,660

Dear Helmut,

❝ ❝ […] In a 2*2 cross-over BE study. If we want to test the Tmax betweent different treatments. Which test statistic should be used? Wilcoxon signed rank test or Wilcoxon rank sum test?

❝ The former (aka Wilcoxon T test).

❝ The latter (aka Mann–Whitney U test, Mann–Whitney–Wilcoxon test, Wilcoxon–Mann–Whitney test) is for independent samples (parallel design).

Here you err!

The Wilcoxon signed rank test1 can only applied if you neglect period effects. It tests the within-subject treatment differences against zero and is therefore a non-parametric analogon of the paired Student t-test.

To account for period effects you have to apply the Wilcoxon–Mann–Whitney test2 with sequence as grouping factor if you evaluate a 2x2 cross-over design. This test is sometimes also called Hauschke test. Guess why :cool:.
In case of a parallel design the grouping factor is of course the treatment, as you correctly stated.

The cited example you quote uses the correct test.
And I suppose Phoenix 8.0 / Crossover object does the same

1 V. W. Steinijans and E. Diletti
"Statistical Analysis of Bioavailability Studies: Parametric and Nonparametric Confidence Intervals"
Eur J Clin Pharmacol (1983) 24:127-136

"A distribution-free procedure for the statistical analysis of bioequivalence studies"
International Journal of Clinical Pharmacology, Therapy and Toxicology,
Vol. 28 No. 2 -1990 (72-78) / Vol.30, Suppl. No. 1 -1992 (pp,S37-43)



Complete thread:

UA Flag
 Admin contact
22,824 posts in 4,786 threads, 1,632 registered users;
36 visitors (0 registered, 36 guests [including 5 identified bots]).
Forum time: 16:29 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz